Demographic and clinical characteristics in patients with EC-ESBL and controls.

*<p>SD: Standard deviation.</p

Molecular characterization of Escherichia coli ESBL.

<p>Molecular characterization of extended-spectrum beta-lactamase <i>Escherichia coli</i> producers (n = 56).</p

Clinical characteristics in patients with EC-ESBL and controls.

*<p>BMT = Bone marrow transplantation.</p

Antimicrobials used in Escherichia coli ESBL and in the control group.

<p>Antimicrobials used during the previous month in extended-spectrum beta-lactamase <i>Escherichia coli</i> and the <i>E.coli</i> control group.</p

Kaplan Meier survival curve for Escherichia coli ESBL and control patients according to antimicrobial treatment.

<p>Kaplan-Meier survival curve for patients with extended-spectrum beta-lactamase <i>Escherichia coli</i> and the <i>E. coli</i> control group, stratified according to appropriate vs. non-appropriate antimicrobial treatment.</p

<i>Escherichia coli</i>-ESBL isolated from 2004 to 2009.

<p>Total number of <i>Escherichia coli</i> extended-spectrum beta-lactamases (ESBL) isolated from blood cultures at Instituto Nacional de Cancerología, Mexico City (2004–2009).</p

Mean survival (days) and outcome according appropriate antimicrobial treatment^*.

*<p>Appropriate antimicrobial treatment was considered when this had been initiated within the first 48 h of first symptoms and if the patient had received this for at least >72 h, including an antibiotic with susceptibility for the isolated <i>E. coli</i> strain.</p